bluebird bio Inc (BLUE.OQ)
BLUE.OQ on NASDAQ Stock Exchange Global Select Market
103.43USD
18 Dec 2018
103.43USD
18 Dec 2018
Change (% chg)
$-1.14 (-1.09%)
$-1.14 (-1.09%)
Prev Close
$104.57
$104.57
Open
$105.62
$105.62
Day's High
$105.62
$105.62
Day's Low
$101.00
$101.00
Volume
387,319
387,319
Avg. Vol
217,917
217,917
52-wk High
$236.05
$236.05
52-wk Low
$99.30
$99.30
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -2.85 | December | 19 Dec 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 8 | 7 | 5 | 5 |
| (2) OUTPERFORM | 8 | 9 | 9 | 9 |
| (3) HOLD | 7 | 6 | 7 | 7 |
| (4) UNDERPERFORM | 0 | 0 | 1 | 1 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.96 | 1.95 | 2.18 | 2.18 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 18 | 8.57 | 12.00 | 0.00 | 7.18 |
| Quarter Ending Mar-19 | 12 | 10.72 | 19.80 | 5.00 | -- |
| Year Ending Dec-18 | 22 | 43.62 | 48.00 | 35.00 | 29.81 |
| Year Ending Dec-19 | 22 | 66.20 | 121.59 | 11.00 | 113.83 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 19 | -2.85 | -2.55 | -3.20 | -1.62 |
| Quarter Ending Mar-19 | 13 | -2.79 | -2.22 | -3.18 | -- |
| Year Ending Dec-18 | 21 | -10.79 | -10.25 | -11.17 | -7.10 |
| Year Ending Dec-19 | 22 | -11.42 | -9.01 | -12.95 | -6.15 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Sep-18 | 7.51 | 11.53 | 4.02 | 53.55 |
| Quarter Ending Jun-18 | 9.64 | 7.85 | 1.79 | 18.58 |
| Quarter Ending Mar-18 | 5.60 | 15.96 | 10.36 | 185.11 |
| Quarter Ending Dec-17 | 7.06 | 4.17 | 2.89 | 40.93 |
| Quarter Ending Sep-17 | 7.07 | 7.71 | 0.64 | 9.06 |
| Earnings (per share) | ||||
| Quarter Ending Sep-18 | -2.87 | -2.73 | 0.14 | -4.88 |
| Quarter Ending Jun-18 | -2.35 | -2.91 | 0.56 | -24.01 |
| Quarter Ending Mar-18 | -2.07 | -2.31 | 0.24 | -11.70 |
| Quarter Ending Dec-17 | -1.70 | -2.52 | 0.82 | -48.14 |
| Quarter Ending Sep-17 | -1.71 | -1.73 | 0.02 | -1.38 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 8.57 | 8.57 | 9.30 | 7.59 | 7.18 |
| Quarter Ending Mar-19 | 10.72 | 10.72 | 11.15 | 8.84 | -- |
| Year Ending Dec-18 | 43.62 | 43.62 | 43.70 | 39.48 | 29.81 |
| Year Ending Dec-19 | 66.20 | 66.20 | 67.27 | 84.72 | 113.83 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | -2.85 | -2.85 | -2.84 | -2.88 | -1.62 |
| Quarter Ending Mar-19 | -2.79 | -2.79 | -2.83 | -2.87 | -- |
| Year Ending Dec-18 | -10.79 | -10.79 | -10.79 | -10.88 | -7.10 |
| Year Ending Dec-19 | -11.42 | -11.42 | -11.48 | -11.01 | -6.15 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 3 | 1 |
| Year Ending Dec-19 | 0 | 0 | 0 | 3 |
| Earnings | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 2 |
Earnings vs. 
Estimates- Amgen antibody shows promise in myeloma trial, gets FDA fast track
- UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track
- Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track
- UPDATE 1-Rare manufacturing glitch raises concern over CAR-T therapies -study
- Rare manufacturing glitch raises concern over CAR-T therapies -study